Monograph Details
|
|
Infections & Infestations
> Malaria
|
|
PLAQUENIL |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Aminoquinoline. |
| Generic Name |
|
Hydroxychloroquine sulfate 200mg; tabs. |
| Indications |
|
Suppression and treatment of susceptible malaria. |
| Children |
|
Suppression (start 2 wks before and continue for 8 wks after trip): 6.45mg/kg (max 400mg) every 7 days. Treatment: initially 12.9mg/kg (max 800mg); then 6.45mg/kg (max 400mg) 6, 24 and 48 hrs after 1st dose. |
| Adults |
|
Suppression (start 2 wks before and continue for 8 wks after trip): 400mg every 7 days. Treatment: initially 800mg; then 400mg 6, 24, and 48 hrs after 1st dose. |
| Contraindications |
|
Long-term use in children. Retinal or visual field changes. |
| Precautions |
|
Before using this product, be fully familiar with its toxicity. Hepatic dysfunction. Alcoholism. Psoriasis. Porphyria. G6PD deficiency. Monitor ocular function, reflexes, and blood in long-term use. Discontinue if blood dyscrasias occur. Children. Pregnancy. Nursing mothers. |
| Interactions |
|
Avoid other hepatotoxic or dermatotoxic drugs. |
| Adverse Reactions |
|
Headache, dizziness, GI upset. |
| How Supplied |
|
Tabs—100 |
|
|
|
|
